Cellular Biomedicine Group (NASDAQ:CBMG) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.
Earnings & Valuation
This table compares Cellular Biomedicine Group and Titan Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cellular Biomedicine Group||$220,000.00||1,378.95||-$38.93 million||($2.04)||-8.22|
|Titan Pharmaceuticals||$220,000.00||109.91||-$14.30 million||($4.20)||-0.44|
Institutional & Insider Ownership
9.2% of Cellular Biomedicine Group shares are held by institutional investors. Comparatively, 30.5% of Titan Pharmaceuticals shares are held by institutional investors. 8.3% of Cellular Biomedicine Group shares are held by company insiders. Comparatively, 6.5% of Titan Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
Cellular Biomedicine Group has a beta of 2.9, meaning that its stock price is 190% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
This table compares Cellular Biomedicine Group and Titan Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cellular Biomedicine Group||-17,386.16%||-42.82%||-40.08%|
This is a breakdown of current recommendations and price targets for Cellular Biomedicine Group and Titan Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cellular Biomedicine Group||0||1||2||0||2.67|
Cellular Biomedicine Group presently has a consensus price target of $32.00, suggesting a potential upside of 90.82%. Titan Pharmaceuticals has a consensus price target of $12.00, suggesting a potential upside of 545.16%. Given Titan Pharmaceuticals’ higher possible upside, analysts plainly believe Titan Pharmaceuticals is more favorable than Cellular Biomedicine Group.
Cellular Biomedicine Group beats Titan Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing; and Novartis to manufacture and supply the CAR-T cell therapy KymriahÂ. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.